

24 April 2025

Treatment for Advanced Ovarian Cancer

1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another Trust, and if so which one?

NB: not all patients had staging in recent documentation. Stages III and IV = 106

2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:

- **Paclitaxel in combination with a platinum-based compound**
34
- **Platinum-based therapy alone (cisplatin or carboplatin)**
<5
- **Bevacizumab in combination with paclitaxel and carboplatin**
14
- **Olaparib**
25
- **Olaparib + Bevacizumab**
<5
- **Niraparib**
54
- **Rucaparib**
<5

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.

24 April 2025

- 3. Does your Trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part?**

ModiFY Study - recruiting

- 4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:**

Not available.

- **Olaparib**
- **Olaparib + Bevacizumab**
- **Niraparib**
- **Other treatments**